Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach

• Published in: Journal of cancer research and clinical oncology Vol. 149; no. 10; pp. 7717 - 7728
• Main Authors: Gordon, S., Chan, D. L. H., Bernard, E. J., Eslick, M. E., Willowson, K. P., Roach, P. J., Engel, A. F., Maher, R., Clarke, S. J., Agarwal, V., Yasmin, L., De Silva, M., Mascall, S., Conner, A., Nevell, D., Pavlakis, N., Bailey, D. L.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.08.2023; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Cancer Research; Female; Hematology; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Molecular Imaging; Myelodysplastic syndrome; Myelodysplastic syndromes; nephrotoxicity; Neuroendocrine tumors; Neuroendocrine Tumors - pathology; Octreotide - therapeutic use; Oncology; pancreas; Patients; peptide receptors; Peptides; Precision Medicine; Radiation therapy; Radioisotopes; Receptors, Peptide; risk; Small intestine; Survival; therapeutics; Toxicity; NETs; Multidisciplinary Team (MDT); Neuroendocrine; PET; Peptide Receptor Radionuclide Therapy (PRRT)

Aim To summarise our centre’s experience managing patients with neuroendocrine tumours (NETs) in the first 5 years after the introduction of peptide receptor radionuclide therapy (PRRT) with [ 177 Lu]Lu-DOTA-octreotate (LUTATE). The report emphasises aspects of the patient management related to func...